GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hansa Biopharma HNSA.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

41.30

+4.66%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in SEK, from our data supplier.

FY2025

Revenue

SEK 222.3m

FY2016FY2025

Net income

−SEK 534.1m

FY2016FY2025

Free cash flow

−SEK 549.2m

FY2016FY2025

Shareholders' equity

−SEK 89.0m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueSEK 222.3mSEK 171.3mSEK 134.1mSEK 154.5mSEK 33.9mSEK 6.1mSEK 3.4mSEK 3.4mSEK 3.4mSEK 2.6m
Research and developmentSEK 304.7mSEK 375.7mSEK 411.3mSEK 346.2mSEK 230.8mSEK 227.2mSEK 192.9mSEK 154.6mSEK 137.1mSEK 82.8m
Operating income−SEK 520.7m−SEK 670.1m−SEK 725.3m−SEK 575.1m−SEK 547.5m−SEK 425.1m−SEK 359.2m−SEK 247.3m−SEK 176.1m−SEK 111.1m
Net income−SEK 534.1m−SEK 807.2m−SEK 831.7m−SEK 611.1m−SEK 548.3m−SEK 420.9m−SEK 360.0m−SEK 248.0m−SEK 176.7m−SEK 111.1m
Diluted earnings per share-5.25-11.90-15.79-13.25-12.33-9.46-8.99-6.20-4.67-3.17

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsSEK 1.17bnSEK 800.6mSEK 1.02bnSEK 1.69bnSEK 1.01bnSEK 1.43bnSEK 664.2mSEK 944.8mSEK 680.4mSEK 310.7m
Cash and short-term investmentsSEK 701.1mSEK 405.3mSEK 732.1mSEK 1.50bnSEK 889.0mSEK 1.38bnSEK 601.1mSEK 858.2mSEK 616.1mSEK 253.6m
Total liabilitiesSEK 1.25bnSEK 1.39bnSEK 1.19bnSEK 1.08bnSEK 255.2mSEK 192.4mSEK 101.4mSEK 84.9mSEK 49.8mSEK 27.0m
DebtSEK 933.8mSEK 1.08bnSEK 866.8mSEK 791.1mSEK 35.4mSEK 5.7mSEK 10.2mSEK 577,000—SEK 48,000
Shareholders' equity−SEK 89.0m−SEK 589.8m−SEK 167.9mSEK 602.9mSEK 757.6mSEK 1.24bnSEK 562.8mSEK 859.9mSEK 630.7mSEK 283.7m
Shares outstanding102m68m53m46m44m44m40m40m38m35m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−SEK 549.2m−SEK 674.9m−SEK 755.7m−SEK 502.7m−SEK 481.2m−SEK 290.3m−SEK 334.8m−SEK 204.6m−SEK 150.1m−SEK 94.6m
Capital spending—−SEK 116,000−SEK 284,000−SEK 3.3m−SEK 2.4m−SEK 294,000−SEK 3.4m−SEK 2.5m−SEK 2.4m−SEK 984,000
Free cash flow−SEK 549.2m−SEK 675.0m−SEK 755.9m−SEK 506.1m−SEK 483.6m−SEK 290.6m−SEK 338.2m−SEK 207.1m−SEK 152.5m−SEK 95.5m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueSEK 48.1mSEK 34.6mSEK 76.0mSEK 30.8mSEK 49.1mSEK 66.3mSEK 32.3mSEK 48.7m
Operating income−SEK 201.4m−SEK 142.1m−SEK 124.9m−SEK 147.9m−SEK 154.7m−SEK 93.4m−SEK 170.5m−SEK 116.9m
Net income−SEK 260.5m−SEK 196.3m−SEK 165.0m−SEK 148.3m−SEK 178.9m−SEK 37.1m−SEK 276.4m−SEK 103.8m
Diluted earnings per share-2.56-1.93-1.62-1.46-1.76-0.36-4.08-1.53
Cash from operations−SEK 103.0m−SEK 156.0m−SEK 177.0m−SEK 89.0m−SEK 111.0m−SEK 151.0m−SEK 206.0m−SEK 148.0m
Capital spending−SEK 18.0m———−SEK 17.0m———
Free cash flow−SEK 121.0m———−SEK 128.0m———
Total assetsSEK 1.07bnSEK 1.16bnSEK 1.17bnSEK 741.1mSEK 837.3mSEK 705.3mSEK 800.6mSEK 940.7m
Cash and short-term investmentsSEK 552.8mSEK 676.5mSEK 701.1mSEK 252.1mSEK 354.4mSEK 250.2mSEK 405.3mSEK 553.5m
DebtSEK 1.03bnSEK 1.14bnSEK 933.8mSEK 923.9mSEK 906.2mSEK 1.02bnSEK 1.08bnSEK 958.2m
Shareholders' equity−SEK 520.2m−SEK 275.3m−SEK 89.0m−SEK 560.7m−SEK 441.1m−SEK 623.7m−SEK 589.3m−SEK 320.0m

Financial ratios

Data as of 21 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-235.1%-391.2%-540.9%-366.5%-1615.9%-6897.9%
Net margin-240.3%-471.2%-620.3%-395.5%-1618.4%-6901.5%
Return on equity600.2%136.9%495.4%-101.4%-72.4%-33.9%
Return on assets-45.8%-100.8%-81.7%-36.2%-54.1%-29.3%
Free cash flow yield-14.1%-26.0%-37.5%-28.5%-28.3%-17.1%
Revenue growth29.7%27.8%-13.2%356.1%455.6%81.3%
Earnings growth-33.8%-2.9%36.1%11.5%30.3%16.9%
Current ratio1.94x2.29x2.66x6.06x5.50x12.20x
Debt to equity-10.46x-1.82x-5.08x1.28x0.01x0.00x
Equity ratio-7.6%-73.7%-16.5%35.7%74.8%86.6%
Interest coverage-4.44x-5.00x-6.87x-12.97x-788.81x-1636.72x
R&D as a share of sales137.1%219.3%306.7%224.1%681.2%3725.7%
Buybacks as a share of market value-50.1%-28.7%-14.2%-3.7%0.0%-11.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue12.9%105.3%44.9%
Operating income-3.3%4.1%22.9%
Net income-4.4%4.9%23.2%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-302.6%-365.2%-479.6%-597.5%
Net margin-340.8%-408.1%-519.7%-636.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-6.5-3.3-1.7-3.7-7.2-25.4-9.3-27.0-32.4-22.3
Price to sales15.715.510.314.7116.6—————

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.